Company Profile
Creo Medical Group PLC is a UK-based manufacturer of minimally invasive electrosurgical and endoscopic devices, headquartered in Chepstow, Monmouthshire, Wales, UK. Founded in 2003 by Professor Chris Hancock, the company operates as a publicly traded entity on the London Stock Exchange AIM (CREO.L), serving gastroenterologists, pulmonologists, and interventional endoscopists across the United Kingdom, Europe, the United States, and Asia-Pacific.
Core Products ＆ Technologies
CROMA Advanced Energy Platform
• CROMA™ Electrosurgery Unit: Patented Kamaptive™ technology platform combining bipolar radiofrequency for precise localized cutting and super high-frequency microwave energy for controlled coagulation and ablation, delivered via a single accessory port
• Speedboat™ Inject: First advanced energy multi-modal instrument for flexible endoscopy delivering both bipolar RF and microwave energy from a single device; features integrated injection needle for submucosal lift without instrument exchange
• Speedboat™ RS2: Endoscopic submucosal dissection instrument with bipolar RF cut, microwave coagulation, protective hull to reduce muscle damage risk, and integrated injection needle
• Speedboat™ UltraSlim: Slimmest advanced energy multi-modal flexible endoscopy instrument in the portfolio
• Speedboat™ Notch: Advanced tissue traction and dissection instrument with innovative notch tip design for depth perception and precise control
Endoscopic Scissor ＆ Ablation Devices
• SpydrBlade™ Flex: Multi-modal endoscopic scissor-type device delivering cutting and coagulation via flexible endoscope; FDA cleared June 2025, commercially launched in Europe March 2025; indicated for Z-POEM, colonic ESD, oesophageal ESD, POEM, and F-POEM
• MicroBlate™ Fine: Smallest flexible tissue microwave needle ablation device for targeted soft tissue ablation
• MicroBlate™ Flex: Microwave ablation device designed for soft tissue ablation in therapeutic endoscopy
Endotherapy Accessories
• Diagnostic ＆ Therapeutic Accessories: Injection needles, haemostatic clips, snares, forceps, and hygiene products for gastroenterology, pulmonology, and urology procedures
Market Position ＆ Certifications
Creo Medical holds a pioneering position in the global advanced energy surgical endoscopy market, competing with Johnson ＆ Johnson and Medtronic in electrosurgical instruments and Olympus in flexible endoscopy. Key strengths include:
• 23+ years of electrosurgery engineering heritage, with Professor Chris Hancock (CTO and Founder) holding 1,200+ patents and elected Fellow of the Royal Academy of Engineering
• Kamaptive™ dual-energy technology: Unique seamless integration of bipolar RF and microwave energy dynamically adapting to patient tissue during resection, dissection, coagulation, and ablation
• Regulatory compliance: CE marked and FDA cleared (CROMA platform, Speedboat family, SpydrBlade Flex); first regulatory clearances achieved in 2017
• Global commercial footprint: Direct sales force in the US and UK, distribution partnerships with Hoya Group / Pentax Medical and Diagmed Healthcare, and APAC hub in Singapore
Corporate Timeline
2003 — Founded in Chepstow, Wales by Professor Chris Hancock to develop medical microwave systems for therapeutic endoscopy
2016 — Completed IPO on the London Stock Exchange AIM
2017 — Achieved first CE Mark and FDA clearances for CROMA and Speedboat; first patient treated with Speedboat
2020–2021 — Acquired Albyn Medical and Boucart Medical; opened US headquarters in Danbury, CT and APAC hub in Singapore
2022 — Professor Chris Hancock elected Fellow of the Royal Academy of Engineering
2024 — Entered UK framework distribution agreement with Diagmed Healthcare
2025 — FDA clearance granted for SpydrBlade™ Flex (June); launched commercially in the UK and Europe (March); American Medical Association introduced reimbursement codes for endoscopic submucosal dissection; revenue grew 50% to £6.0 million
2026 — Q1 revenue grew approximately 60% year-over-year; upgraded full-year revenue growth guidance to 50%–60%; announced £5.5 million placing and proposed sale of 49% stake in Creo Medical Europe SL; secured £2 million conditional loan notes from Development Bank of Wales
Target Markets ＆ Applications
• Therapeutic gastroenterology: Endoscopic submucosal dissection (ESD), peroral endoscopic myotomy (POEM), and Zenker＇s myotomy (Z-POEM) for pre-cancerous and cancerous lesions
• Colorectal and oesophageal intervention: Colonic ESD and oesophageal ESD using multi-modal advanced energy instruments
• Soft tissue ablation: Microwave ablation for targeted lesion treatment in flexible endoscopy
Contact Information
Global Headquarters
Address: Beaufort Park, Beaufort Park Way, Unit 2, Chepstow, Monmouthshire NP16 5UH, UK
Phone: +44 1291 606 005
United States Headquarters
Address: Danbury, Connecticut, USA
Parent Company
Creo Medical Group PLC operates as an independent, publicly traded entity with no parent company.
Stock: London Stock Exchange AIM: CREO.L
Website: creomedical.com
Investor Relations: info@creomedical.com
